Membranous Nephropathy Market Summary
The Membranous Nephropathy market is expected to witness significant growth across the seven major markets (7MM) through 2036, supported by increasing disease awareness, improved diagnosis, and the development of targeted therapies. The United States is projected to remain the largest market owing to higher treatment adoption, favorable reimbursement, and greater healthcare spending.
Membranous nephropathy is the second most common nephropathy in adults after focal segmental glomerulosclerosis (FSGS). Primary membranous nephropathy (PMN) accounted for the largest market share in 2025 due to its high prevalence as an autoimmune kidney disorder. The disease commonly affects individuals between 50–60 years of age and occurs more frequently in males. According to the National Kidney Foundation, nearly 70% of PMN cases are associated with PLA2R antibodies.
Despite advances in disease understanding, there are currently no approved therapies specifically indicated for membranous nephropathy. Existing treatment relies on supportive care and immunosuppressive agents, which are associated with variable efficacy, safety concerns, and high treatment costs. However, an expanding pipeline featuring targeted therapies such as Obinutuzumab, Zanubrutinib, Felzartamab, Povetacicept, ALXN1920, and Budoprutug is expected to transform the treatment landscape. Novel mechanisms including dual BAFF/APRIL inhibition, BTK inhibition, anti-CD20, anti-CD38, and complement-targeted therapies are anticipated to improve long-term disease control and patient outcomes.
Explore DelveInsight’s Full Coverage on the Membranous Nephropathy Market
Membranous Nephropathy Overview
Membranous nephropathy is a rare autoimmune glomerular disease characterized by immune complex deposition along the glomerular basement membrane, resulting in nephrotic syndrome, proteinuria, edema, hypoalbuminemia, and progressive kidney dysfunction. The disease is classified into primary (idiopathic) and secondary forms. Primary disease is commonly associated with autoantibodies against PLA2R or THSD7A, whereas secondary disease may develop due to infections, autoimmune disorders, malignancies, or certain medications.
Membranous Nephropathy Diagnosis and Treatment Algorithm
Diagnosis involves clinical evaluation, laboratory testing, serologic assessment for biomarkers such as anti-PLA2R antibodies, and kidney biopsy, which remains the diagnostic gold standard. Biomarker-guided diagnosis has significantly improved disease monitoring and treatment selection.
Current management focuses on reducing proteinuria and preserving kidney function through supportive care, including ACE inhibitors or ARBs, diuretics, lipid-lowering therapy, and anticoagulation where appropriate. Immunosuppressive therapies such as corticosteroids, cyclophosphamide, calcineurin inhibitors, and rituximab are widely used, although none are specifically approved for membranous nephropathy. Multiple targeted therapies are being developed to address this unmet need.
Explore the complete Membranous Nephropathy Market report for comprehensive pipeline, epidemiology, and forecast insights
Membranous Nephropathy Market Players
Key companies operating in the market include Roche, BeOne Medicines, Biogen, Vertex Pharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Climb Bio, and others.
Membranous Nephropathy Epidemiology
The epidemiology section provides historical and forecasted patient population estimates across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, offering insights into disease prevalence and future trends.
Key Findings:
- Primary membranous nephropathy represented nearly 85% of total membranous nephropathy cases in the US in 2025.
- PLA2R-positive disease accounted for the majority of idiopathic membranous nephropathy cases across the 7MM.
- EU4 and the UK included nearly 20,000 PLA2R-positive patients and around 1,000 THSD7A-positive patients in 2025.
- Japan is expected to maintain relatively stable disease prevalence throughout the forecast period (2026–2036).
- Improved diagnosis and increasing awareness are expected to support continued growth in the identified patient population.
Membranous Nephropathy Market Outlook
The membranous nephropathy market is expected to expand steadily through 2036, driven by advances in biomarker-guided diagnosis, increasing understanding of autoimmune disease mechanisms, and the emergence of targeted immunotherapies.
Current treatment depends primarily on supportive care and conventional immunosuppressants, highlighting a significant unmet clinical need. The next generation of therapies is focused on selective B-cell depletion, plasma-cell targeting, BTK inhibition, complement inhibition, and dual BAFF/APRIL blockade. Obinutuzumab, Zanubrutinib, Felzartamab, Povetacicept, ALXN1920, and Budoprutug are among the leading candidates expected to reshape the treatment landscape.
The United States is anticipated to remain the largest market due to early adoption of innovative biologics, favorable reimbursement policies, and increasing investment in nephrology research.
Emerging Membranous Nephropathy Drugs
The pipeline is advancing rapidly with multiple late-stage therapies designed to improve efficacy while minimizing long-term immunosuppression.
- Obinutuzumab (GAZYVA/GAZYVARO, RG7159, GA101) – Roche
Obinutuzumab is a glycoengineered anti-CD20 monoclonal antibody developed for enhanced B-cell depletion. Already approved for lupus nephritis and several hematologic malignancies, it has the potential to become the first approved therapy for primary membranous nephropathy. In February 2026, Roche announced positive Phase III MAJESTY results, and the company expects BLA submission during 2026.
- Zanubrutinib (BRUKINSA) – BeOne Medicines
Zanubrutinib is an oral BTK inhibitor currently being evaluated in the Phase III ALMOND trial for primary membranous nephropathy. Its oral administration offers improved convenience while suppressing autoreactive B-cell signaling and pathogenic autoantibody production.
- Felzartamab – Biogen
Felzartamab is an anti-CD38 monoclonal antibody targeting plasma cells responsible for pathogenic autoantibody production. Phase III development is ongoing, with potential approval anticipated between 2028 and 2030.
- Povetacicept – Vertex Pharmaceuticals
Povetacicept is a dual BAFF/APRIL inhibitor designed to suppress both B-cell maturation and plasma-cell survival. The therapy received US FDA Fast Track Designation in 2025 and is currently progressing through Phase II/III development.
Membranous Nephropathy Drugs Uptake
The report evaluates the expected uptake of emerging therapies launched during the forecast period by assessing market penetration, competitive positioning, clinical efficacy, safety, regulatory progress, pricing assumptions, and physician adoption. Targeted biologics with differentiated mechanisms are expected to gain significant market share as they address key unmet needs beyond conventional immunosuppressive therapy.
Request a complimentary sample to discover emerging therapies, competitive intelligence, and future Membranous Nephropathy market opportunities
Conclusion
The Membranous Nephropathy market is poised for robust growth through 2036 as advances in autoimmune disease research, biomarker-driven diagnosis, and targeted therapeutics reshape the treatment landscape. Although current management relies largely on supportive care and non-specific immunosuppression, late-stage pipeline candidates such as Obinutuzumab, Zanubrutinib, Felzartamab, and Povetacicept have the potential to become disease-modifying therapies that improve long-term renal outcomes. Continued innovation, expanding clinical research, and increasing recognition of rare kidney diseases are expected to create significant opportunities for patients, healthcare providers, and industry stakeholders.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: abhishek@delveinsight.com
